JP Morgan Chase’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-28
| Closed | – | – | 7257 |
|
|
2021
Q3 | $0 | Hold |
28
| – | – | ﹤0.01% | 7027 |
|
|
2021
Q2 | $0 | Hold |
28
| – | – | ﹤0.01% | 6779 |
|
|
2021
Q1 | $0 | Sell |
28
-47,338
| -100% | -$247K | ﹤0.01% | 6506 |
|
|
2020
Q4 | $205K | Buy |
47,366
+7,131
| +18% | +$30.5K | ﹤0.01% | 4801 |
|
|
2020
Q3 | $166K | Sell |
40,235
-77,719
| -66% | -$301K | ﹤0.01% | 4453 |
|
|
2020
Q2 | $302K | Sell |
117,954
-35,234
| -23% | -$104K | ﹤0.01% | 4081 |
|
|
2020
Q1 | $443K | Buy |
153,188
+143,272
| +1,445% | +$642K | ﹤0.01% | 3874 |
|
|
2019
Q4 | $38K | Buy |
9,916
+2,514
| +34% | +$12K | ﹤0.01% | 5205 |
|
|
2019
Q3 | $38K | Buy |
7,402
+1,200
| +19% | +$7.41K | ﹤0.01% | 5262 |
|
|
2019
Q2 | $37K | Buy |
6,202
+773
| +14% | +$4.45K | ﹤0.01% | 5292 |
|
|
2019
Q1 | $39K | Sell |
5,429
-255
| -4% | -$2.29K | ﹤0.01% | 5217 |
|
|
2018
Q4 | $49K | Buy |
5,684
+596
| +12% | +$7.75K | ﹤0.01% | 5086 |
|
|
2018
Q3 | $102K | Sell |
5,088
-153,449
| -97% | -$3.6M | ﹤0.01% | 4946 |
|
|
2018
Q2 | $4.09M | Sell |
158,537
-84,749
| -35% | -$2.35M | ﹤0.01% | 2829 |
|
|
2018
Q1 | $5.81M | Sell |
243,286
-22,453
| -8% | -$708K | ﹤0.01% | 2450 |
|
|
2017
Q4 | $9.01M | Buy |
265,739
+129,466
| +95% | +$3.61M | ﹤0.01% | 2199 |
|
|
2017
Q3 | $2.84M | Buy |
136,273
+135,235
| +13,028% | +$2.48M | ﹤0.01% | 2944 |
|
|
2017
Q2 | $18K | Sell |
1,038
-152,725
| -99% | -$2.53M | ﹤0.01% | 4559 |
|
|
2017
Q1 | $2.69M | Sell |
153,763
-26,621
| -15% | -$454K | ﹤0.01% | 2851 |
|
|
2016
Q4 | $3.05M | Buy |
180,384
+16,934
| +10% | +$262K | ﹤0.01% | 2812 |
|
|
2016
Q3 | $2.68M | Buy |
163,450
+7,651
| +5% | +$116K | ﹤0.01% | 2627 |
|
|
2016
Q2 | $2.36M | Buy |
155,799
+41,693
| +37% | +$687K | ﹤0.01% | 2723 |
|
|
2016
Q1 | $1.65M | Buy |
114,106
+59,125
| +108% | +$996K | ﹤0.01% | 2802 |
|
|
2015
Q4 | $1.56M | Sell |
54,981
-6,747
| -11% | -$114K | ﹤0.01% | 2894 |
|
|
2015
Q3 | $1.03M | Buy |
61,728
+1,339
| +2% | +$30.5K | ﹤0.01% | 3080 |
|
|
2015
Q2 | $1.58M | Sell |
60,389
-6,211
| -9% | -$121K | ﹤0.01% | 3039 |
|
|
2015
Q1 | $1.17M | Sell |
66,600
-3,500
| -5% | -$60K | ﹤0.01% | 3153 |
|
|
2014
Q4 | $1.22M | Buy |
70,100
+57,600
| +461% | +$874K | ﹤0.01% | 3243 |
|
|
2014
Q3 | $233K | Sell |
12,500
-34,060
| -73% | -$586K | ﹤0.01% | 3953 |
|
|
2014
Q2 | $851K | Buy |
+46,560
| New | +$834K | ﹤0.01% | 2916 |
|
JP Morgan Chase's ADMS Position: Q4 2021 in Review
JP Morgan Chase sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 28 shares.
JP Morgan Chase first reported a position in ADMS in Q2 2014 and held it in 30 quarters. The position peaked at $9.01M in Q4 2017. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- JP Morgan Chase reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- JP Morgan Chase sold 28 Adamas Pharmaceuticals shares in Q4 2021.
- JP Morgan Chase first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 30 quarters.
- JP Morgan Chase's Adamas Pharmaceuticals position peaked at $9.01M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on JP Morgan Chase's 13F filing for Q4 2021, filed 10 Feb 2022.